SOTIO
Jankovcova 1518/2
Prague 7
170 00
Tel: 420-224-175-111
Website: http://www.sotio.com/
Email: sotio@sotio.com
46 articles with SOTIO
-
SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab
1/19/2023
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group,announced today that the first patient was dosed in its Phase 2 AURELIO-05 combination trial of nanrilkefusp alfa (previously known as SOT101), an IL-15 superagonist, and cetuximab in patients with colorectal cancer.
-
SOTIO Presents Preclinical Data from BOXR CAR-T Program and Trial Design of Phase 2 AURELIO-04 Study at SITC Annual Meeting
11/10/2022
SOTIO Biotech presented preclinical dataevaluating the mechanism of action and metabolic function of its BOXR T cell platform in a poster presentation at the Society for Immunotherapy of Cancer 37th Annual Meeting, taking place in Boston, Massachusetts from November 8-12, 2022.
-
Biopharma and life science companies added changes to their leadership teams this week, with Cara Therapeutics, SOTIO Biotech, Agenus, and more filling several C-suite positions.
-
InMed updated its INM-755 for patients with epidermolysis bullosa, Seagen and Astellas announced positive topline results for Padcev with Merck’s Keytruda, and more.
-
SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)
7/26/2022
SOTIO Biotech announced today that the first patient was dosed in its Phase 2, AURELIO-04 combination trial.
-
Oral Presentation of Interim Data from the AURELIO-03 Study of SOT101 at the 2022 ASCO Annual Meeting
4/27/2022
SOTIO Biotech announced that it will deliver an oral presentation featuring interim safety and efficacy data from the Phase 1/1b AURELIO-03 study with its IL-15 superagonist, SOT101, as monotherapy and in combination with pembrolizumabat the upcoming American Society of Clinical Oncology Annual Meeting 2022, taking place in Chicago, Illinois fromJune 3-7, 2022.
-
SOTIO Initiates CLAUDIO-01 Trial with Antibody-Drug Conjugate SOT102 in Patients with Gastric and Pancreatic Cancer
4/26/2022
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it has dosed the first patient in its Phase1/2 CLAUDIO-01 trial of SOT102 in patients with gastric and pancreatic cancer.
-
BioSpace looked at some of the efforts to improve the host system’s immune response, as well as others to improve allogeneic or autologous cell transplants.
-
This year’s AACR Annual Meeting is coming to a close, and there has been a wealth of information and data presented. One topic of discussion stood out—mutations.
-
Interim Data from the Phase 1/1b AURELIO-03 Trial of SOT101 Presented at the AACR 2022 Annual Meeting
4/12/2022
SOTIO Biotech, a clinical stage immuno-oncology companyowned by PPF Group, today announced interim safety and efficacy results from the ongoing Phase 1/1b AURELIO-03 study of SOT101, an IL-15 superagonist, in combination with pembrolizumab in patients with advanced/metastatic solid tumors.
-
SOTIO Announces Oral and Multiple Poster Presentations on Key Clinical Programs at the American Association of Cancer Research Annual Meeting (AACR) 2022
3/16/2022
SOTIO Biotech announced today that it will deliver an oral presentation featuring interim safety and efficacy data from its Phase 1/1b AURELIO-03 study with its IL-15 superagonist, SOT101, in combination with pembrolizumab, as well as two poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, taking place in New Orleans, Louisiana, April 8-13, 2022.
-
SOTIO Secures €280m of Funding to Expand and Advance Clinical Pipeline
12/2/2021
SOTIO Biotech, a clinical stage immuno-oncology companyowned by PPF Group,announced that is has secured€280m of funding to significantly expand and advance its clinical pipeline, including its lead assetSOT101, an IL-15 superagonist, and three new clinical programs until the end of 2023.
-
Biopharma and life sciences companies from across the globe provide updates. Belgium-based Galapagos NV won European approval for Jyseleca for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
-
SOTIO to Present New Data from Phase 1 Study of IL-15 Superagonist, SOT101, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
11/3/2021
SOTIO will present three posters discussing data that highlight the encouraging safety and efficacy for SOT101 (SO-C101) as a monotherapy and in combination with pembrolizumab for the treatment of advanced solid tumors
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
SOTIO Presents Positive Biomarker Data from DCVAC/OvCa Phase 2 Study in First Line Ovarian Cancer at the 2021 ASCO Annual Meeting
6/4/2021
SOTIO , a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of positive biomarker data from its Phase 2 trial with dendritic cell vaccine DCVAC/OvCa during a virtual poster presentation at the 2021 ASCO Annual Meeting. DCVAC/OvCa is being developed as a first line treatment in adults with ovarian cancer.
-
SOTIO to Present Biomarker Data from its SOV01 – DCVAC/OvCa Phase 2 Study in 1st line Ovarian Cancer at the 2021 ASCO Annual Meeting
5/11/2021
SOTIO , a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 ASCO Annual Meeting.
-
BioSpace Global Roundup, Nov. 12
11/12/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
BioSpace Global Roundup, Nov. 5
11/5/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
SOTIO to Present at BIO-Europe Digital 2020
10/26/2020
SOTIO , a clinical stage immuno-oncology company owned by PPF Group, today announced that Jens Hennecke, chief business officer of SOTIO, is presenting at BIO-Europe Digital being held on October 26 - 29 , 2020 . The presentation will be made available on demand on the Bio Europe website and accessible to attendees registered for the event. The 26th annual BIO-Europe global life sciences partnering event is